EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial
Abstract
Authors
S. Swami O. Hale I. Thornton D. Muston M.J. Monberg B.J. Monk